Data to Establish the Optimal Standard Regimen and Predicting the Response to Docetaxel Therapy

Overview

Journal Data Brief

Date 2015 Nov 24

PMID 26594654

Citations 1

Authors

Emad Y Moawad

Affiliations

Soon will be listed here.

Abstract

This paper contains data to establish the optimal standard regimen and predicting the response to docetaxel therapy (Moawad, 2014) [1]. Docetaxel has been in use for over a decade without demonstrating data indicates a predictable response in the treatment of cancer. Data of puzzling response to docetaxel therapy was due to its cell cycle specific effect. Although several administered schedules were investigated, the relative therapeutic advantage of high versus low doses has not been identified yet. Also the antitumor target of docetaxel has not yet been identified to optimize therapy by predicting the response of patients prior to therapy to provide a protection against treatment failure. In the present paper, we demonstrate the data used to optimize docetaxel therapy and investigate the possibility of predicting for the first time the antitumor target of docetaxel.

Citing Articles

Statistical data analysis of cancer incidences in insurgency affected states in Nigeria.

Adamu P, Oguntunde P, Okagbue H, Agboola O Data Brief. 2018; 18:2029-2046.

PMID: 29904711 PMC: 5998707. DOI: 10.1016/j.dib.2018.04.135.

References

Moawad E . Isolated system towards a successful radiotherapy treatment. Nucl Med Mol Imaging. 2014; 44(2):123-36. PMC: 4079774. DOI: 10.1007/s13139-010-0029-9. View

Ichite N, Chougule M, Jackson T, Fulzele S, Safe S, Singh M . Enhancement of docetaxel anticancer activity by a novel diindolylmethane compound in human non-small cell lung cancer. Clin Cancer Res. 2009; 15(2):543-52. PMC: 2866624. DOI: 10.1158/1078-0432.CCR-08-1558. View

Moawad E . Clinical and pathological staging of the cancer at the nanoscale. Cancer Nanotechnol. 2015; 3(1-6):37-46. PMC: 4451867. DOI: 10.1007/s12645-012-0028-x. View

Moawad E . Administering the Optimum Dose of l-Arginine in Regional Tumor Therapy. Indian J Clin Biochem. 2014; 29(4):442-51. PMC: 4175696. DOI: 10.1007/s12291-013-0379-z. View

Yoo G, Subramanian G, Boinpally R, Iskander A, Shehadeh N, Oliver J . An in vivo evaluation of docetaxel delivered intratumorally in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 2005; 131(5):418-29. DOI: 10.1001/archotol.131.5.418. View

Li Y, Kucuk O, Hussain M, Abrams J, Cher M, Sarkar F . Antitumor and antimetastatic activities of docetaxel are enhanced by genistein through regulation of osteoprotegerin/receptor activator of nuclear factor-kappaB (RANK)/RANK ligand/MMP-9 signaling in prostate cancer. Cancer Res. 2006; 66(9):4816-25. DOI: 10.1158/0008-5472.CAN-05-3752. View

Banerjee S, Hussain M, Wang Z, Saliganan A, Che M, Bonfil D . In vitro and in vivo molecular evidence for better therapeutic efficacy of ABT-627 and taxotere combination in prostate cancer. Cancer Res. 2007; 67(8):3818-26. DOI: 10.1158/0008-5472.CAN-06-3879. View

Williams J, Muenchen H, Kamradt J, Korenchuk S, Pienta K . Treatment of androgen-independent prostate cancer using antimicrotubule agents docetaxel and estramustine in combination: an experimental study. Prostate. 2000; 44(4):275-8. DOI: 10.1002/1097-0045(20000901)44:4<275::aid-pros3>3.0.co;2-9. View

Sweeney C, Mehrotra S, Sadaria M, Kumar S, Shortle N, Roman Y . The sesquiterpene lactone parthenolide in combination with docetaxel reduces metastasis and improves survival in a xenograft model of breast cancer. Mol Cancer Ther. 2005; 4(6):1004-12. DOI: 10.1158/1535-7163.MCT-05-0030. View

10.

Liu T, Zhang M, Zhang H, Sun C, Yang X, Deng Y . Combined antitumor activity of cucurbitacin B and docetaxel in laryngeal cancer. Eur J Pharmacol. 2008; 587(1-3):78-84. DOI: 10.1016/j.ejphar.2008.03.032. View

11.

Moawad E . Induction of multiple sclerosis and response to tyrosine kinase inhibitors. Indian J Clin Biochem. 2014; 29(4):491-5. PMC: 4175700. DOI: 10.1007/s12291-013-0387-z. View

12.

Moawad E . Identifying the optimal dose of ritonavir in the treatment of malignancies. Metab Brain Dis. 2013; 29(2):533-40. DOI: 10.1007/s11011-013-9448-5. View

13.

Moawad E . Predicting Effectiveness of Imatinib Mesylate in Tumors Expressing Platelet-Derived Growth Factors (PDGF-AA, PDGF-BB), Stem Cell Factor Ligands and Their Respective Receptors (PDGFR-α, PDGFR-β, and c-kit). J Gastrointest Cancer. 2015; 46(3):272-83. DOI: 10.1007/s12029-015-9721-4. View

14.

Moawad E . Optimal standard regimen and predicting response to docetaxel therapy. Mutat Res. 2015; 770:120-7. DOI: 10.1016/j.mrfmmm.2014.08.006. View

15.

Moawad E . Radiotherapy and risks of tumor regrowth or inducing second cancer. Cancer Nanotechnol. 2015; 2(1-6):81-93. PMC: 4451625. DOI: 10.1007/s12645-011-0018-4. View

16.

Moawad E . Optimizing and predicting the in vivo activity of AT9283 as a monotherapy and in combination with paclitaxel. J Gastrointest Cancer. 2015; 46(4):380-9. DOI: 10.1007/s12029-015-9761-9. View

17.

Kamat A, Kim T, Landen Jr C, Lu C, Han L, Lin Y . Metronomic chemotherapy enhances the efficacy of antivascular therapy in ovarian cancer. Cancer Res. 2007; 67(1):281-8. DOI: 10.1158/0008-5472.CAN-06-3282. View

18.

Moawad E . Optimizing bioethanol production by regulating yeast growth energy. Syst Synth Biol. 2013; 6(3-4):61-8. PMC: 3528888. DOI: 10.1007/s11693-012-9099-6. View